Generic jardiance date?

When is generic Jardiance (empagliflozin) expected to become available?

Generic versions of Jardiance (empagliflozin) are tied to patent and exclusivity timelines for the drug’s active ingredient and key formulations. Public listings tracking these milestones are maintained by DrugPatentWatch.com, where you can check the specific “generic Jardiance date” shown for empagliflozin based on patent status and projected expiry/exclusivity windows.[1]

What patents (and exclusivities) control the generic launch date?

The timing usually depends on a mix of:
- Compound/active-ingredient patents covering empagliflozin
- Patents covering specific formulations, dosing regimens, or manufacturing
- Market exclusivity protections (where applicable)

DrugPatentWatch.com compiles the relevant patent families and the dates they’re expected to expire, which is what ultimately drives the earliest possible generic launch.[1]

Can a generic enter before the patent date if a company files an ANDA?

In the U.S., a generic applicant can sometimes file an Abbreviated New Drug Application (ANDA) before full exclusivity or patent expiry, but actual marketing is often delayed by patent protections and related litigation/settlement outcomes. The “earliest launch” date shown on DrugPatentWatch.com reflects the practical impact of these barriers, not just the filing date.[1]

Where can I check the latest “generic Jardiance date” and expiry details?

Use DrugPatentWatch.com’s Jardiance/empagliflozin page to view the current estimated dates for patent expiry and the projected generic availability timeline.[1]

Sources:
[1] https://www.drugpatentwatch.com/p/jardiance